Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
768.980.16%
QQQ
720.070.15%
BTC/USD
78694.040.501%
DIA
530.880.6%
GLD
403.910.7%
TLT
82.000.26%

Dyne Therapeutics Inc (DYN) Stock Price, Quote, News & History

DYNNASDAQ
Trade with Public
Trade with Public
$24.28
-0.67-2.69%
At close: Sep 3, 5:00 PM EST
$18.00
-6.95-27.86%
Pre-Market: 6:21 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Dyne Therapeutics (DYN) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
-
Close
$24.28
Volume / Avg.
89.28K / 2.21M
Day Range
- - -
52 Wk Range
11.92 - 27.31
Market Cap
$3.36B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
17
Short Interest
14.7%
Days to Cover
10.95

Recent Dyne Therapeutics, Inc. News

Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket

iSpecimen surged 27.9% premarket on a $4.5M Foldlab AI asset deal; CEA Industries led gainers, while Focus Universal plunged 51.2%.
Avi Kapoor

Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

Pegasystems Inc (NASDAQ: PEGA) reported lower-than-expected earnings and sales, causing stocks to fall 16% in pre-market trading.
Avi Kapoor

Dyne Therapeutics Stock Tumbles After Hours: Here's Why

Dyne Therapeutics stock fell after hours after pricing an upsized $375M public offering of common stock.
Tanya Rawat

Nio, Zevra Therapeutics, Vertex Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

Dow Jones index up 200 points on Tuesday, NIO Inc. gained following better-than-expected financial results and Capricor Therapeutics announced a new PDUFA date for Deramiocel BLA.
Avi Kapoor

Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday

US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer treatment data. Hims & Hers and Xenon Pharma jump over 40%.
Avi Kapoor

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-477.82M
Investing Cash Flow (TTM)
-44.17M
Financing Cash Flow (TTM)
713.47M
Free Cash Flow (TTM)
-499.22M
Capital Expenditure (TTM)
-21.40M
Net Change in Cash (TTM)
191.48M

Analyst Trends and Forecast

1
Mar
1
1
May
1
Jun
3
Jul
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
3.9
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$3.85B
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
-
PB Ratio (TTM)
6.45
Earnings Yield % (TTM)
-13.43%
Earnings Yield % (FWD)
-13.25%
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$3.76

Company Debt

Total Debt
$199.33M
LT Debt
$199.33M
LT Debt Issuance (TTM)
$98.90M
LT Debt Repayment (TTM)
-
Total Cash
$676.11M
Debt to Equity
0.31
Issuance of Debt (TTM)
$98.90M
Repayment of Debt (TTM)
-

Key Statistics

Open
-
Close
$24.28
Volume / Avg.
89.28K / 2.21M
Day Range
- - -
52 Wk Range
11.92 - 27.31
Market Cap
$3.36B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
17
Short Interest
14.7%
Days to Cover
10.95

About

Sector
Health Care
Industry
Biotechnology
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therape...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy Dyne Therapeutics (DYN) stock?

A

You can purchase shares of Dyne Therapeutics (NASDAQ:DYN) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Dyne Therapeutics (DYN) competitors?

Q

What is the forecast, or price target, for Dyne Therapeutics (DYN) stock?

A

Dyne Therapeutics has a consensus price target of $40.14.

Q

What is the current price for Dyne Therapeutics (DYN)?

A

The stock price for Dyne Therapeutics (NASDAQ: DYN) is $18 last updated September 8, 2026 at 6:21 AM EDT.

Q

Does Dyne Therapeutics (DYN) pay a dividend?

A

There are no upcoming dividends for Dyne Therapeutics.

Q

When is Dyne Therapeutics (NASDAQ:DYN) reporting earnings?

A

Dyne Therapeutics does not have any upcoming earnings scheduled.

Q

Is Dyne Therapeutics (DYN) going to split?

A

There is no upcoming split for Dyne Therapeutics.

Q

What sector and industry does Dyne Therapeutics (DYN) operate in?

A

Dyne Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved